



Global Medical REIT Inc. (GMRE)

Updated November 19th, 2024 by Nikolaos Sismanis

Key Metrics

Current Price:	\$8.61	5 Year CAGR Estimate:	10.3%	Market Cap:	\$598.3 M
Fair Value Price:	\$8.50	5 Year Growth Estimate:	3.0%	Ex-Dividend Date:	12/26/2024 ¹
% Fair Value:	101%	5 Year Valuation Multiple Estimate:	-0.3%	Dividend Payment Date:	01/09/2025
Dividend Yield:	9.8%	5 Year Price Target	\$9.85	Years Of Dividend Growth:	N/A
Dividend Risk Score:	F	Retirement Suitability Score:	C	Rating:	Buy

Overview & Current Events

Global Medical REIT Inc. is a net-lease medical office REIT that acquires specialized healthcare facilities, which it leases to national healthcare systems and industry-leading physician groups. Its portfolio consists of gross investments in real estate worth around \$1.4 billion. They comprise 187 facilities with an aggregate of 4.8 million leasable square feet (LSF) and an aggregate of \$107.8 million of annualized base rent. About 71% of the REIT's leasable square footage (LSF) is comprised of Medical Office Buildings (MOB), 18% is dedicated to Inpatient Rehabilitation Facilities (IRF), and the remaining 11% is allocated to other specialized facilities. The \$598.3 million company is based in Bethesda, Maryland.

On November 6th, 2024, Global Medical reported its Q3 results for the period ending September 30th, 2024. Revenues came in at nearly \$34.3 million, a 3.5% decline year-over-year. The decline reflects the company's property dispositions during this period and lower occupancy. At the end of the quarter, occupancy stood at 96.1%, 10 bps lower sequentially. AFFO fell by 7.3% to \$15.3 million, due to lower revenues. On a per-share basis, AFFO came in one cent lower, at \$0.22. Further, the weighted average lease term for the REIT's portfolio was 5.6 years, while the weighted average annual rental escalations was 2.2%. For fiscal 2024, we continue to expect AFFO/share of \$0.85.

Growth on a Per-Share Basis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
AFFO/shr²	---	(\$0.88)	(\$0.03)	\$0.54	\$0.76	\$0.75	\$0.88	\$0.95	\$0.98	\$0.91	\$0.85	\$0.99
DPS	---	\$1.02	\$0.74	\$0.80	\$0.80	\$0.80	\$0.80	\$0.82	\$0.84	\$0.84	\$0.84	\$0.84
Shares³	---	0.3	9.3	19.6	22.0	33.9	46.3	60.6	65.5	65.6	65.7	90.0

Global Medical has rapidly grown its healthcare property portfolio, enjoying robust cash flows and high-quality tenants. The company's solid occupancy and extended average lease period are able to sustain stable financials even under adverse conditions such as those caused by COVID-19 in 2020, a year of record AFFOs at the time.

We expect the main catalyst for future AFFO/share growth to be acquisitions and annual rent escalations. We retain our AFFO/share annual growth estimate at 3% through 2029 as a rising-rates environment could hurt the company's bottom-line growth prospects. Higher rates also explain our lower AFFO/share estimate for FY2024, despite ongoing deleveraging efforts.

In terms of its dividend, combined with its preferred shares, the company had been paying out more to shareholders than it was earning up until 2019. This was most likely to attract investors amid the continuous share issuances that it constantly executes to grow its portfolio. It was essential to keep the share price as high as possible during such times. Eventually, Global Medical's AFFO/share caught up with the dividend post-2020. However, a rather tough healthcare real estate environment has pressured AFFO/share lately. We don't expect further dividend increases moving forward.

¹ Estimated dates based on past dividend dates.

² Being a REIT, AFFO/share is more meaningful metric than EPS. The trust reports high depreciation and amortization levels.

³ Share count is in millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Global Medical REIT Inc. (GMRE)

Updated November 19th, 2024 by Nikolaos Sismanis

Valuation Analysis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Now	2029
Avg. P/AFFO	---	---	---	17.0	12.5	15.3	14.2	15.7	12.9	9.9	10.1	10.0
Avg. Yld.	---	---	7.4%	8.7%	8.4%	7.0%	6.4%	5.4%	6.6%	10.2%	9.8%	8.5%

Global Medical's stock currently trades around 10.1 times our expected FY2024 AFFO/share. Global Medical offers rather humble growth prospects due to a tough healthcare real estate environment, while high interest rates imply an elevated risk premium. Thus, we believe the current multiple is fair. The 9.9% yield should attract investors to the stock. Still, it also reflects the underlying risks attached to the REIT's payouts, including razor-thin coverage.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
Payout	---	---	---	148%	105%	107%	91%	86%	86%	92%	99%	85%

Global Medical's dividend is likely not safe in the current market environment. Recent property dispositions by management to accumulate capital in order to deleverage reflects their defensive posture in the face of recent challenges. That said, the company does feature some qualities. Specifically, no state accounts for more than 19% of its rental revenues, while no tenant accounts for more than 7.4% of its annualized base rent. Hence, the company enjoys adequate diversification qualities. Still, due to its small market cap and immature profile compared to its largest peers, the company faces higher financing costs. Whether it is its hefty dividend (cost of share issuance) or its (admittedly better) cost of debt, which currently stands at 3.79%, the company is likely to be subject to lower profit margins until the macroeconomic landscape improves. Further, we don't see any meaningful competitive advantages, while the REIT's short history as a publicly-traded company is also something to be wary of.

Final Thoughts & Recommendation

Global Medical REIT is a niche healthcare real estate trust featuring robust rental revenues, satisfactory diversification, and an above-average dividend yield, which should remain covered. We forecast annualized returns of 10.3% through 2029, primarily powered by the 9.8% yield and our humble per-share growth estimate. Shares earn a speculative buy rating.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Global Medical REIT Inc. (GMRE)

Updated November 19th, 2024 by Nikolaos Sismanis

Income Statement Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Revenue	1	2	8	30	53	71	94	116	137	141
Gross Profit		2	8	28	49	65	83	100	112	113
Gross Margin	0.0%	96.1%	99.1%	93.9%	93.0%	91.6%	88.4%	86.2%	81.8%	80.1%
SG&A Exp.	0	1	6	9	10	13	16	16	17	17
D&A Exp.	0	1	2	10	18	26	37	47	58	59
Operating Profit	0	1	0	10	22	27	31	37	39	38
Operating Margin	15.6%	26.0%	1.3%	32.5%	41.8%	38.6%	32.6%	31.9%	28.5%	27.0%
Net Profit	(0)	(2)	(6)	(0)	13	9	(2)	17.6	19	21
Net Margin	-68.7%	-78.0%	-77.4%	-0.1%	25.4%	13.1%	-2.1%	15.2%	13.9%	14.9%
Free Cash Flow	0	(32)	(153)	(240)	(159)	(220)	(184)	(133)	(80)	58

Balance Sheet Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Total Assets	24	65	227	472	636	885	1,101	1,263	1,393	1,268
Cash & Equivalents	0	9	20	5	4	3	6	7	4	1,278
Accounts Receivable	0	-	0	1	3	5	6	6	8	7
Goodwill & Int. Ass.		-	7	29	36	59	80	94	97	72
Total Liabilities	23	65	72	213	336	425	643	626	744	662
Accounts Payable		1	1	2	4	5	7	10	14	13
Long-Term Debt	22	64	67	201	315	386	587	571	694	611
Shareholder's Equity	2	(0)	155	171	194	355	370	548	558	509
LTD/E Ratio	12.72	(461)	0.43	0.81	1.17	0.90	1.32	0.92	1.10	1.05

Profitability & Per Share Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Assets	-1.8%	-3.6%	-4.3%	0.0%	2.4%	1.2%	-0.2%	1.5%	1.4%	1.6%
Return on Equity	-20.8%	-203%	-8.2%	0.0%	7.4%	3.4%	-0.5%	3.8%	3.5%	3.3%
ROIC	-1.8%	-3.7%	-4.5%	0.0%	2.5%	1.3%	-0.2%	1.6%	1.5%	1.6%
Shares Out.		0.3	9.3	19.6	22.0	33.9	46.3	60.6	65.5	65.6
Revenue/Share	2.39	8.25	0.88	1.55	2.42	2.09	2.03	1.91	2.10	2.15
FCF/Share	0.52	(127)	(16.4)	(12.2)	(7.22)	(6.51)	(3.98)	(2.19)	(1.22)	0.89

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.